Disease landscape

Bladder Cancer clinical trials

Get alerts when Bladder Cancer trials change

816 active trials 453 recruiting 90 Phase 3 412 sponsors 104 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 56 of 104 changes on 20 trials

2026-08-04
Trial status changed: Completed → Terminated
Trial terminated: Study was closed early as the sponsor decided not to continue development of certain treatment combinations.
NCT03869190 Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and… · Hoffmann-La Roche · Phase 1/2
2026-08-25
Trial terminated
Primary completion moved earlier: 2028-12-31 → 2026-07-01
Completion moved earlier: 2029-12-31 → 2026-07-31
NCT03185468 Intervention of Bladder Cancer by CAR-T · Shenzhen Geno-Immune Medical Institute · Phase 1/2
2026-08-14
Trial status changed: Completed → Terminated
Trial terminated: Accrual and drug manufacturing and supply were discontinued in 2025.
NCT02769962 Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With… · National Cancer Institute (NCI) · Phase 1/2
2026-08-14
Withdrawn before enrolling
Trial withdrawn: Study withdrawn prior to enrollment. Principle Investigator changed institutions prior to obtaining IRB approval.
Enrollment reduced: 190 → 0 participants
NCT07655284 STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy · Brigham and Women's Hospital · Phase 3
2026-08-15
Primary completion pushed: 2027-09 → 2028-01-31
Completion pushed: 2030-06 → 2030-10-31
Trial arms changed: 3 → 2
NCT07393542 A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial… · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Phase 3
2026-08-08
Primary completion pushed: 2026-06-30 → 2028-04-30
Completion pushed: 2028-11-30 → 2030-10-30
NCT04752722 LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely… · enGene, Inc. · Phase 1/2
2026-07-30
Primary completion pushed: 2026-10-30 → 2033-07
Primary endpoint(s) modified
Enrollment reopened
Enrollment increased: 296 → 340 participants
Completion pushed: 2027-05-12 → 2033-07
Trial arms changed: 14 → 15
NCT04198766 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in… · Inhibrx Biosciences, Inc · Phase 1/2
2026-08-18
Primary completion pushed: 2026-08-31 → 2027-08-31
Completion pushed: 2026-08-31 → 2027-12-31
NCT05519241 A Phase I Intravesical PPM Therapy for NMIBC · VA Office of Research and Development · Phase 1
2026-08-25
Primary completion pushed: 2026-05-31 → 2027-05-31
Completion pushed: 2026-05-31 → 2027-05-31
NCT00902590 A Genotype-Phenotype Urothelial Cancer Registry · Memorial Sloan Kettering Cancer Center
2026-08-21
Primary completion pushed: 2027-03-02 → 2028-08
Enrollment reduced: 50 → 20 participants
Recruitment opened
Completion pushed: 2027-03-02 → 2028-08
NCT07548476 Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy · Dana-Farber Cancer Institute
2026-08-04
Primary completion pushed: 2026-04 → 2028-04
Sponsor changed: University of British Columbia → Peter Black
Trial sites expanded: 4 → 8 locations
Completion pushed: 2026-04 → 2028-06
NCT06124976 Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma · Peter Black · Phase 2/3
2026-08-26
Primary endpoint(s) modified
NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… · Lumina Pharmaceuticals Inc · Early Phase 1
2026-08-08
Primary completion pushed: 2026-08-31 → 2028-08-31
Completion pushed: 2026-08-31 → 2028-08-31
NCT05137262 A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI… · M.D. Anderson Cancer Center · Phase 2
2026-08-22
Primary endpoint(s) modified
Recruitment opened
Enrollment increased: 56 → 299 participants
Trial sites expanded: 0 → 3 locations
Primary completion moved earlier: 2028-08 → 2027-08
Trial arms changed: 2 → 3
NCT07623369 A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors · Huahui Health · Phase 1
2026-08-21
Primary endpoint(s) modified
Enrollment increased: 535 → 677 participants
Trial arms changed: 5 → 8
NCT05614739 FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With… · Eli Lilly and Company · Phase 1
2026-07-30
Primary endpoint(s) modified
NCT04640623 A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in… · Janssen Research & Development, LLC · Phase 2
2026-08-06
Primary endpoint(s) modified
Primary completion moved earlier: 2030-06-28 → 2027-01-31
Trial arms changed: 7 → 9
NCT05176483 Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in… · Exelixis · Phase 1
2026-08-21
Primary endpoint(s) modified
Trial arms changed: 4 → 5
NCT05269381 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for… · Mayo Clinic · Phase 1/2
2026-08-15
Primary endpoint(s) modified
Phase changed: Phase 1 → Phase 1/2
Enrollment increased: 55 → 115 participants
NCT05126472 Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond… · Memorial Sloan Kettering Cancer Center · Phase 1/2
2026-08-06
Primary endpoint(s) modified
Enrollment increased: 47 → 75 participants
NCT06809140 Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of… · Matthew Galsky · Phase 2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-25 NCT07783815 A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab… Xiangya Hospital of Central South University new Phase 1
2026-08-25 NCT07784387 A Study to Characterize High-Risk Non-Muscle-Invasive Bladder Cancer Participants in… Janssen-Cilag Farmaceutica Ltda. new
2026-08-24 NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… Lumina Pharmaceuticals Inc new Early Phase 1
2026-08-24 NCT07781956 Home-Based Supportive Care Program for NMIBC Patients Receiving Intravesical Perfusion… Nanjing First Hospital, Nanjing Medical University new
2026-08-24 NCT07780838 Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for the… Ohio State University Comprehensive Cancer Center new Phase 2
2026-08-24 NCT07782164 Efficacy of Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors… Amsterdam UMC, location VUmc new
2026-08-17 NCT07767994 AK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer First Affiliated Hospital Xi'an Jiaotong University new Phase 2
2026-08-11 NCT07758881 Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for… Eight Medical International BV new
2026-08-10 NCT07756437 Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper… AZ Sint-Lucas Gent new
2026-08-06 NCT07750470 Diagnostic Accuracy of 18F-FDG PET/CT in Muscle-invasive Bladder Cancer University Hospital of Ferrara new

Active trials by phase

Early Phase 1
11
Phase 1
105
Phase 1/2
75
Phase 2
202
Phase 2/3
17
Phase 3
73
Phase 4
7
Not charted: 326 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 816

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT06862219 A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer Astellas Pharma Global Development, Inc. Recruiting 2026-08-21
NCT06764095 Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally… Mayo Clinic Recruiting 2026-02-12
NCT05962541 Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic… University of Roma La Sapienza Recruiting 2025-12-31
NCT06781879 Chemoablation Or Bladder Resection With Adjuvant Chemotherapy in Recurrent Non-Muscle… Jakob Kristian Jakobsen Recruiting 2025-10-03
NCT04532606 Impact of Remimazolam on Prognosis After Bladder Cancer Surgery Peking University First Hospital Recruiting 2025-07-30
NCT06709196 Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections… Rigshospitalet, Denmark Recruiting 2025-01-09
NCT06548438 The Impact of PDD During TURB for NMIBC A.O.U. Città della Salute e della Scienza Not Yet Recruiting 2024-08-12
Phase 3
NCT06524544 A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus… National Cancer Institute (NCI) Recruiting 2026-08-26
NCT07419295 A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer… Merck Sharp & Dohme LLC Recruiting 2026-08-24
NCT07218380 A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract Eli Lilly and Company Recruiting 2026-08-21
NCT07480356 Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of… Protara Therapeutics Recruiting 2026-08-21
NCT06929286 A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer… Memorial Sloan Kettering Cancer Center Recruiting 2026-08-20
NCT07097142 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients… NRG Oncology Recruiting 2026-08-18
NCT04865939 Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma University of Texas Southwestern Medical Center Recruiting 2026-08-17
NCT07393542 A Trial of SHR-A2102 With Adebrelimab in Locally Advanced or Metastatic Urothelial… Suzhou Suncadia Biopharmaceuticals Co., Ltd. Recruiting 2026-08-14
NCT06510374 Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk… Ferring Pharmaceuticals Recruiting 2026-08-06
NCT06545955 A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With… Ferring Pharmaceuticals Recruiting 2026-08-06
NCT07566156 Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy… Astellas Pharma Global Development, Inc. Recruiting 2026-08-06
NCT07000084 Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone)… Alliance for Clinical Trials in Oncology Recruiting 2026-08-05
NCT06960577 Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients… AstraZeneca Recruiting 2026-08-04
NCT06919965 A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants… Janssen Research & Development, LLC Recruiting 2026-07-31
NCT07720284 An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs… AstraZeneca Recruiting 2026-07-22
NCT06703476 A Study of Surgical Techniques During Cystectomy Memorial Sloan Kettering Cancer Center Recruiting 2026-07-13
NCT06319820 A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in… Janssen Research & Development, LLC Recruiting 2026-07-06
NCT06774131 A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract… UroGen Pharma Ltd. Recruiting 2026-06-16
See all 816 active Bladder Cancer trials with filters →

Top sponsors by active trials in this area

National Cancer Institute (NCI) (33) · Memorial Sloan Kettering Cancer Center (23) · M.D. Anderson Cancer Center (17) · Merck Sharp & Dohme LLC (13) · Peking University First Hospital (12) · AstraZeneca (11) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (11) · Mayo Clinic (10) · RenJi Hospital (10) · Tianjin Medical University Second Hospital (10)

Get alerts when Bladder Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free